Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 1.906 EUR -5.36% Market Closed
Market Cap: 309.5m EUR
Have any thoughts about
Valneva SE?
Write Note

P/E
Price to Earnings

17.9
Current
-9.9
Median
22.7
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
17.9
=
Market Cap
309.5m EUR
/
Net Income
17.3m EUR
All Countries
Close
Market Cap P/E
FR
Valneva SE
PAR:VLA
309.5m EUR 17.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 532.6
US
Abbvie Inc
NYSE:ABBV
314.7B USD 61.9
US
Amgen Inc
NASDAQ:AMGN
147.4B USD 34.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD -248.8
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 903.4
US
Epizyme Inc
F:EPE
94.1B EUR -473.3
AU
CSL Ltd
ASX:CSL
135.4B AUD 33.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -54.8
NL
argenx SE
XBRU:ARGX
34.3B EUR -129.4
Earnings Growth
FR
Valneva SE
PAR:VLA
Average P/E: 178.2
17.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 532.6 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
34.9
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -248.8
42%
US
Gilead Sciences Inc
NASDAQ:GILD
903.4
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -473.3 N/A
AU
CSL Ltd
ASX:CSL
33.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.4 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-92.5
2-Years Forward
P/E
-5.1
3-Years Forward
P/E
-12.9

See Also

Discover More